Replies to post #952 on GTC Biotherapeutics (fka GTCB)

[jessellivermore]

The future.

I would like add to my previous post and some of the excellant posts by Urche and value and others.

Never mind the fact the market has apparently snoozed thru the event today, or there has been a nasty dilution. The event is great news for all longs. The announced agreement means is for the first time the plasma protein industry has recognized the transgenic production technique as a feasible way to produce clincal grade protiens in quanity. This single strategic allience means no one in the industry can afford to ignore GTCB any longer.

The revolution has begun.

[DewDiligence]

>…it sounds like there might be a small slip in the ATryn hereditary deficiency US FDA BLA timeline. Cox guided for completion of patient enrollment in H1 2007 (previous Q1 2007?) and submission of the BLA in H2 2007 (previously Q3 2007?).<

You’re correct—the old guidance for the U.S. ATryn timeline is as stated in #msg-12432067. However, this is a pretty small matter in the overall scheme of things, IMO.